Aethlon medical inc (AEMD)
CashFlow / Yearly
Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11
Cash flows used in operating activities:
NET LOSS

-6,219

-5,699

-7,306

-4,958

-6,979

-13,438

-4,892

-

-

Net income (loss)

-

-

-

-

-

-

-

-8,111

-5,711

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

30

35

32

38

37

21

10

17

19

Costs associated with issuance of warrants

-

-

-

-

-

-

-

-

74

Stock based compensation

1,319

1,260

2,186

202

416

607

765

758

1,774

Debt restructuring cost

-

-

-

-

-

856

139

-

-

Legal fees paid through the issuance of convertible debt

-

-

-

-

-

-

-

-

63

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

766

6,079

Loss on extension of warrants

-

-

-

-

143

0

-

-

-

Loss on debt extinguishment

0

-376

-558

0

-2,753

-

-

-77

-3,306

Warrant repricing expense

-

-

345

0

-

-

-

-

-

(Gain) on share for warrant exchanges

0

-130

0

-

-

-

-

-

-

Patent license fees paid with issuance of common stock

-

-

-

-

-

-

17

17

17

Liquidated damages

-

-

-

-

-

-

-

-

149

Amortization of debt discount and deferred financing costs

121

245

220

517

273

5

594

2,598

2,027

Loss on litigation settlement

-

-

-

-

-

583

0

-

-

Change in estimated fair value of derivative liabilities

-

-

-

-

-

8,547

44

-

-

Loss on debt conversion

-

-

-

-

-

-40

-

-

-

Loss on debt conversion

-

-

-

-

-

-

0

0

-

Loss on settlement of convertible note termination

-

-

-

-

-

-

-

360

-

Common stock issued for services

19

33

0

-

225

392

259

341

672

Income taxes

-

-

-

-

-

-

-

-

0

Conversion of debt, accrued liabilities and accrued interest to common stock

0

362

144

0

2,273

726

1,695

2,058

1,563

Debt discount on notes payable associated with embedded conversion feature and detachable warrants

-

-

-

-

-

-

-

-

1,750

Recording deferred financing costs associated with convertible notes payable

-

-

-

-

-

-

-

-

254

Reclassification of warrant derivative liability into equity

-

-

-

-

-

-

45

289

-

Debt discount on notes payable associated with embedded conversion feature and detachable warrants

-

-

-

-

-

-

-

1,362

-

Reclassification of accounts payable to convertible notes payable

-

-

-

-

-

47

0

124

-

Reclassification of accrued interest to convertible notes payable

-

-

85

0

25

20

0

-

-

Issuance of shares for warrants

-

-

0

0

-

-

-

-

-

Issuance of shares under vested restricted stock units

0

0

0

0

-

-

-

-

-

Recording deferred financing costs associated with convertible notes payable

-

-

-

-

117

-

-

-

-

Recording deferred financing costs associated with notes payable and convertible notes payable

-

-

-

-

-

83

7

367

-

Reclassification of warrant derivative liability into equity

-

-

-

-

10,679

1,456

-

-

-

Issuance of shares under cashless warrant exercises

-

-

0

0

0

12

0

-

-

Debt discount on convertible notes payable

-

-

783

0

-

-

-

-

-

Exercise of stock option for accrued expenses

-

-

-

-

-

13

0

-

-

Creation of debt discount on convertible notes payable

-

-

-

-

527

0

-

-

-

Reclassification of note payable to convertible notes payable

-

-

-

-

-

-

75

0

-

Stock issued under restricted stock grant

-

-

-

-

-

3

0

-

-

Non-cash rent expense

-

-

-

-

-

-

11

694

1,252

Changes in operating assets and liabilities:
Accounts receivable

-74

74

-199

6

98

-113

-191

-400

-

Prepaid expenses and other current assets

28

143

-15

-19

22

21

-1

-1

37

Other assets

-6

3

-7

95

-2

8

0

5

-5

Accounts payable and other current liabilities

390

-104

322

-46

-1,108

46

751

920

394

Due to related parties

-6

32

-87

-1

-692

116

6

112

-

Due to related parties

-

-

-

-

-

-

-

-

38

Net cash used in operating activities

-4,293

-3,910

-3,505

-4,329

-5,049

-2,138

-2,098

-1,841

-1,968

Cash flows from investing activities:
Purchases of property and equipment

0

24

16

9

0

96

0

1

2

Patents and patents pending

-

-

-

-

-

-

-

-

6

Net cash used in investing activities

0

-24

-16

-9

0

-96

0

-1

-9

Cash flows provided by (used in) financing activities:
Proceeds from collection of secured notes receivable

-

-

-

-

-

-

-

200

500

Proceeds from the issuance of common stock, net, value

-

-

-

-

4,763

3,177

2,109

300

320

Cash paid for repurchase of restricted stock units

193

278

378

0

-

-

-

-

-

Proceeds from the issuance of notes payable

-

-

-

-

-

400

0

-

-

Principal repayments of notes payable

-

-

-

-

523

217

29

223

-

Proceeds from the issuance of convertible notes payable

-

-

577

0

415

-

-

1,694

1,105

Net proceeds from the issuance of common stock and exercise of warrants

1,341

9,628

2,759

5,606

-

-

-

-

-

Net provided by financing activities

1,147

9,349

2,958

5,606

4,654

3,360

2,080

1,971

1,925

Net decrease in cash

-3,145

5,414

-564

1,268

-394

1,125

-18

128

-52

Supplement disclosures of cash flow information:
Interest

95

0

-

-

-

-

-

-

-

Interest

-

-

-

-

480

13

2

29

-

Income taxes

-

-

-

-

-

0

0

0

-

Supplemental information of non-cash investing and financing activities:
Issuance of note receivable in connection with convertible debt financing

-

-

-

-

-

-

-

-

400